Amneal Pharmaceuticals Inc (NYSE:AMRX) disclosed on Monday the receipt of US FDA approval for the generic version of the transdermal product Exelon Patch (Rivastigmine Transdermal System) in 4.6 mg/24 hours, 9.5 mg/24 hours and 13.3 mg/24 hours.
Following US FDA approval, the company said it intends to launch its Rivastigmine Transdermal System shortly.
For the 12 months ended November 2018, the US market annual sales for Rivastigmine Transdermal System is estimated at about USD225m, according to IQVIA,
Headquartered in Bridgewater, NJ, Amneal is a pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval